Henry Schein, Inc. (NASDAQ:HSIC) Stock Has Consensus Price Target of $92.93 According to Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received an average rating of “Moderate Buy” from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $92.93.

Several brokerages have recently issued reports on HSIC. Barclays reissued an “overweight” rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, August 21st. BMO Capital Markets assumed coverage on shares of Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 target price on the stock. Barrington Research set a $104.00 target price on shares of Henry Schein in a report on Wednesday, August 5th. Finally, Stifel Nicolaus set a $95.00 price target on shares of Henry Schein in a research report on Wednesday, August 5th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Operose Advisors LLC purchased a new position in shares of Henry Schein in the 2nd quarter valued at about $33,000. Trust Co. of Vermont purchased a new stake in shares of Henry Schein during the second quarter worth approximately $42,000. Versant Capital Management Inc raised its holdings in Henry Schein by 175.4% in the second quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock valued at $52,000 after acquiring an additional 393 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Henry Schein by 167.4% in the first quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock valued at $69,000 after acquiring an additional 586 shares in the last quarter. Finally, Contravisory Investment Management Inc. purchased a new position in Henry Schein in the second quarter worth approximately $84,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Down 0.1%

NASDAQ:HSIC opened at $84.88 on Monday. Henry Schein has a 52 week low of $61.94 and a 52 week high of $92.18. The stock’s fifty day moving average is $87.80 and its two-hundred day moving average is $81.39. The stock has a market capitalization of $9.46 billion, a price-to-earnings ratio of 24.75, a price-to-earnings-growth ratio of 1.50 and a beta of 0.84. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The business had revenue of $3.46 billion during the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the previous year, the firm posted $1.10 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Research analysts anticipate that Henry Schein will post 5.36 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of health care products and services serving dental and medical professionals, laboratories, health care institutions and veterinary practices. The company operates primarily as a distributor, helping customers obtain medical, dental and veterinary supplies, equipment, pharmaceuticals and related products.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support practice management, clinical workflows, procurement, compliance and business operations.